Biocon raises ₹4,500 crore through QIP
The QIP, which opened on June 16 and closed on June 19, witnessed robust investor interest from a diverse group of domestic and international investors, underscoring strong confidence in Biocon's growth prospects, said the company on Friday.
Siddharth Mittal, CEO and Managing Director, Biocon Limited, said, 'The strong response to our QIP reflects deep investor conviction in Biocon's differentiated strategy and consistent execution. This capital raise further strengthens our balance sheet, enabling us to invest in innovation, expand global access to lifesaving biopharmaceuticals, and advance our purpose of delivering affordable healthcare solutions that address pressing health inequities worldwide.'
According to the company, this fundraise, the first equity fundraise done by Biocon since its IPO in 2004, demonstrates the company's access to a diversified equity pool of capital.
The final order book was well diversified in terms of investor type across domestic mutual funds, insurance companies and foreign institutional investors. Some of the leading names who participated in the issue included SBI Mutual Fund, ICICI Prudential Mutual Fund, HDFC Life Insurance, Nippon India Mutual Fund, Mirae Asset Mutual Fund, Aditya Birla Mutual Fund, Franklin Templeton, SBI General Insurance, Government Pension Fund Global and Blackrock, the biotech firm further said.
The proceeds from the QIP would be utilised towards purchase of outstanding optionally convertible debentures issued by Biocon Subsidiary, Biocon Biologics Limited, from Goldman Sachs India AIF Scheme - 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2. Also, proceeds would be used for repayment, pre-payment or redemption, in full or in part, of certain outstanding financial instruments issued and/or borrowings availed by the company, and/or meeting other financial commitments of the company; and for general corporate purposes, as per the company.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
9 hours ago
- Business Standard
Biocon climbs 3% on plans to file approvals for generic weight-loss drug
Biocon share price rose 2.5 per cent in trade on Wednesday, logging an intraday high at ₹371.5 per share on BSE. The buying on the counter came after reports suggested that the company plans to file for regulatory approvals of generic versions of Novo Nordisk A/S's Ozempic and Wegovy. Ozempic is primarily used for managing blood sugar in adults with type 2 diabetes. Wegovy, on the other hand, is approved for long-term weight management in adults and adolescents with obesity or who are overweight and have weight-related health problems. Biocon will start phase-3 trials for semaglutide in India 'soon,' and plans to file for approval by the end of next year, Siddharth Mittal, managing director, Biocon said. At 12:08 PM, Biocon share price was trading 2.18 per cent higher at ₹370.25 per share on the BSE. In comparison, the BSE Sensex was trading down 0.19 per cent at 83,537.33. The company's market capitalisation stood at ₹49,501.08 crore. Its 52-week high was at ₹404.6 per share and 52-week low was at ₹290.8 per share. Novo launched Wegovy in India last month, following Eli Lilly & Co.'s Mounjaro entry, as those Western drugmakers seek to tap the country with the world's third-largest obese population. Eli Lilly's Mounjaro has a longer runway with patent protection, which doesn't expire until at least 2030 in most countries. Biocon is joining the leagues of the world's largest generic drugmakers, which includes Sandoz Group AG, in eyeing the weight-loss drug market in Canada, where Novo is set to lose patent protection on semaglutide early next year. The company is expected to forfeit exclusive rights in many other markets from 2026, with patents in India expiring around April of next year. That patent expiration does not include the US, Europe or Japan. The drugmaker also is looking to sell GLP-1 therapies in Latin American countries such as Brazil and Mexico, along with Asia-Pacific markets like Malaysia, Hong Kong, Australia, New Zealand and in its home base of India.
Time of India
9 hours ago
- Time of India
The college-to-CEO journey: Here's what India's top company leaders studied
Every student choosing their degree wonders: will this lead to real success? The answer lies in examining India's most powerful business leaders, whose educational journeys reveal surprising patterns about how academic choices translate into corporate leadership. From engineering graduates running financial empires to commerce students building technology giants, India's top CEOs demonstrate that success stems from combining solid educational foundations with strategic career pivots. Their stories offer valuable insights for students navigating today's competitive landscape, showing how different academic paths can lead to extraordinary achievements. Natarajan Chandrasekaran - Tata Sons Chairman Chandrasekaran began his education in a Tamil medium government school in Mohanur before pursuing Applied Sciences from Coimbatore Institute of Technology and completing his MCA from NIT Tiruchirappalli. Without an IIT or IIM pedigree, he now leads India's largest conglomerate worth over $100 billion. His technical foundation positioned him perfectly for India's technology boom. Rajesh Gopinathan - Former TCS CEO Gopinathan studied electrical engineering at NIT Tiruchirappalli before earning his PGDM from IIM Ahmedabad. This combination of technical depth and management expertise created the ideal foundation for leading one of the world's largest IT services companies through digital transformation. Kiran Mazumdar-Shaw - Biocon Founder After studying zoology at Bangalore University, Mazumdar-Shaw pursued a Master Brewer degree from Ballarat College, Australia. Her unconventional brewing background became her competitive advantage when founding Biocon. The fermentation expertise proved essential in biotechnology manufacturing, creating unique advantages in an emerging industry. Sanjiv Mehta - Former Hindustan Unilever CEO Mehta qualified as a Chartered Accountant before completing Harvard's Advanced Management Programme. His CA training provided crucial financial analysis skills during crisis management and throughout his international career spanning Bangladesh, Philippines, and Africa. Aditya Puri - Former HDFC Bank CEO Puri earned his commerce degree from Punjab University before qualifying as a Chartered Accountant. This combination enabled him to build HDFC Bank into India's most valuable private sector bank. His systematic approach to risk management helped navigate multiple economic cycles. Uday Kotak - Kotak Mahindra Bank CEO Kotak completed his commerce degree from Sydenham College before pursuing Management Studies at Jamnalal Bajaj Institute. Starting with just ₹3 lakh in 1985, he leveraged his foundational business education to build one of India's leading financial institutions. What can students learn from their journeys? These leaders prove 3 critical principles that challenge conventional wisdom: Excellence transcends institutional prestige: Chandrasekaran and Gopinathan attended regional colleges, not IITs, yet became industry titans. Academic excellence and practical application often matter more than brand names. Unconventional paths create advantages: Mazumdar-Shaw's brewing background initially seemed limiting but provided unique expertise for biotechnology entrepreneurship. Students shouldn't fear unusual academic combinations if they align with emerging opportunities. Professional qualifications drive mobility: Mehta and Puri show how chartered accountancy provides transferable skills valuable across industries and geographies, offering analytical frameworks crucial for business leadership. For today's students, the education backgrounds of these CEOs provides key insights for success. Focus on building transferable skills like analytical thinking and strategic reasoning. Choose programs that develop these capabilities, whether through engineering, commerce, or professional qualifications. Success depends more on how you leverage your education than the specific institution you attend. Is your child ready for the careers of tomorrow? Enroll now and take advantage of our early bird offer! Spaces are limited.
Mint
11 hours ago
- Mint
6200% returns in one year! Multibagger stock hits upper circuit; here's why
Elitecon International share price hit the upper circuit for the third straight session on Wednesday. Elitecon International shares were locked at 5% upper circuit limit of ₹ 69.67 apiece on the BSE. The gains in Elitecon International share price today comes after the company announced the board meeting date for fundraising. The Board of Directors of Elitecon International at its meeting held on Tuesday, July 01, 2025, decided to defer the consideration and approval of raising funds to the next Board meeting which is scheduled to be held on Friday, July 04, 2025. The company's board of directors on July 4 will discuss and evaluate the proposal for raising funds up to an amount of ₹ 75 crores by way of preferential allotment, issue of convertible warrants, Foreign Currency Convertible Bonds (FCCBs), Qualified Institutional Placement (QIP) or any other permissible instruments, subject to necessary approvals from Shareholders, regulatory bodies and other stakeholders. In a separate regulatory filing, Elitecon International said that the Statutory Auditors Report on the Annual Audited Financial Results (Standalone & Consolidated) of the Company for the financial year ended March 31, 2025 do not contain any qualifications, reservations or adverse remarks. 'The Statutory Auditors of the Company have issued unmodified opinion/unqualified opinion on the Annual Audited Standalone Financial Results (Standalone & Consolidated) of the Company for the financial year ended March 31, 2025,' Elitecon International said in a stock exchange filing. Elitecon International share price has rallied 48% in one month, and more than 106% in three months. The stock has jumped 572% on a year-to-date (YTD) basis, and has delivered multibagger returns of 6,200% in one year. At 10:40 AM, Elitecon International share price was still locked at 5% upper circuit of ₹ 69.67 apiece on the BSE. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
